RxDoctor Payments Data

Mariana Chavez Macgregor

Internal Medicine · Houston, TXNPI 1740408624

Payments from drug & device makers

$636,218in general payments, 2019–2025

Across 156 payments — averaging $4078.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$415K
  • Genentech, Inc.$58K
  • Pfizer$41K
  • Astrazeneca UK Limited$28K
  • Merck$25K
  • AstraZeneca$17K
  • plus $53K from 8 others
$14,522in research payments, 2019–2025

Across 10 payments — averaging $1452.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$10K
  • Pfizer$2K
  • Novartis$1K
  • F. Hoffmann-la Roche AG$760

What the payments were for

  • Consulting fees$134,69372%
  • Speaking & faculty fees$32,51317%
  • Travel & lodging$19,89111%
  • Food & beverage$9671%
  • Education$1630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis5$415,194
Genentech, Inc.11$57,880
Pfizer(2 entities)61$41,241
Astrazeneca UK Limited18$27,590
Merck14$24,689
AstraZeneca16$16,889
Astrazeneca AB8$15,300
Dr.reddy's Laboratories,inc.6$10,950
F. Hoffmann-la Roche AG6$10,118
Eli Lilly3$6,400
Daiichi Sankyo Inc.4$3,708
Daiichi Sankyo Company LTD1$2,740
Pfizer S.A.1$2,200
Roche Products Limited2$1,320

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$636,218 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$21,034
Medicare patients
66
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PiqrayAlpelisib11$241,083
IbrancePalbociclib17$161,934
KisqaliRibociclib Succinate11$142,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisPiqray, Kisqali$415,194$383,38022 claims
PfizerIbrance$41,241$161,93417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →